bluebird bio (BLUE) Reports Strategic Collaboration with TC BioPharm to Research and Develop Gamma Delta CAR T … – StreetInsider.com
Endpoints News |
bluebird bio (BLUE) Reports Strategic Collaboration with TC BioPharm to Research and Develop Gamma Delta CAR T …
StreetInsider.com bluebird bio, Inc. (NASDAQ: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s … Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm’s tumor invading tech platformEndpoints News TC BioPharm teams up with bluebird bio to develop gamma delta CAR TsSeeking Alpha Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived …NB Herard |
|
LSPN Europe 2017: Broad had ‘no clue’ about CRISPR licensing in agriculture
Life Sciences Intellectual Property Review One of the key players in the CRISPR landscape initially had “no clue” about licensing the technology in the agricultural sector. Issi Rozen, chief business officer of the Broad Institute of Harvard and MIT, revealed this yesterday, December 6, while … |
|
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β …
GlobeNewswire (press release) “CRISPR Therapeutics is pioneering a new class of medicines with the CTA submission for CTX001 to conduct the first company-sponsored clinical trial of a CRISPR gene-edited therapy,” commented Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR … Canada’s AmorChem launches $44.2M life science fund; Neon adds $36M, Merck partnership in neoantigen drive …Endpoints News Crispr Therapeutics (NASDAQ:CRSP) Getting Somewhat Favorable News Coverage, Study FindsDispatch Tribunal Analyst Stock Ratings: CRISPR Therapeutics AG (CRSP), T2 Biosystems, Inc. (TTOO)Analyst Journal |
|
There are 2004 cancer immunotherapies crowding into the pipeline. Now what?
Endpoints News Before raising the issue, the CRI — which specializes in immunotherapies — wanted to present a clear picture of the scene to everyone in the field. By assigning two tumor immunologists to comb through a variety of global trial databases over a year’s … |